🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Lilly's tirzepatide shows promise in treating severe OSA

Published 2024/06/21, 22:04
© Reuters.

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) disclosed results from their phase 3 clinical trials of tirzepatide, showcasing its efficacy in treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. The studies, published in The New England Journal of Medicine and presented at the American Diabetes Association’s 84th Scientific Sessions, revealed that tirzepatide significantly reduced the apnea-hypopnea index (AHI) – a measure of OSA severity – by up to 62.8%, equating to roughly 30 fewer events per hour.

Furthermore, a substantial number of participants achieved what was defined as disease resolution. In the highest dose group, 43.0% in the first study and 51.5% in the second study met the criteria for disease resolution, which includes an AHI of fewer than 5 events per hour or an AHI of 5-14 with an Epworth Sleepiness Scale score of ≤10.

OSA is not only a disruptor of daily life but also a contributor to serious cardiometabolic issues such as hypertension and type 2 diabetes. The participants treated with tirzepatide also showed improvements in systolic blood pressure, hypoxic burden, and levels of high-sensitivity C-reactive protein, an inflammation marker.

Atul Malhotra, MD, emphasized the potential of tirzepatide to enhance the treatment landscape for patients with OSA and obesity, nearly half of whom achieved disease resolution in the trials.

The safety profile of tirzepatide was consistent with previous studies, with gastrointestinal issues being the most commonly reported side effects. These were generally mild to moderate in severity.

Eli Lilly has submitted tirzepatide for the treatment of moderate-to-severe OSA and obesity to the U.S. Food and Drug Administration (FDA), with the anticipation of regulatory action by the end of the year. The company plans to initiate submissions to other global regulatory agencies in the coming weeks.

In other recent news, Eli Lilly and Company has been in the spotlight due to a series of developments. The company saw its share target lifted to $957 by Jefferies, following a positive review of the Alzheimer's treatment, Donanemab. Barclays (LON:BARC) also maintained an Overweight rating on Eli Lilly's stock, underscoring the potential benefits of Donanemab's approval for the Alzheimer's drug market.

Additionally, Texas's 25th congressional district representative, Roger Williams, has been active in the stock market, purchasing Eli Lilly stocks valued between $1,001 and $15,000. These transactions were conducted through his Edward Jones Brokerage Accounts. These are some of the recent developments concerning Eli Lilly and Company.

InvestingPro Insights

As Eli Lilly and Company (NYSE: LLY) makes strides with their phase 3 clinical trials of tirzepatide, the company's financial health remains robust, reflected in its significant market capitalization of 797.74 billion USD. This indicates a strong investor belief in the company's value and future prospects, especially as it continues to innovate in the healthcare sector with potential breakthrough treatments like tirzepatide.

Investors are also eyeing the company's high Price/Earnings (P/E) ratio, which stands at a striking 129.73. While this suggests a premium valuation, it's important to note that the adjusted P/E ratio for the last twelve months as of Q1 2024 is lower at 83.82. This could signal that investors are willing to pay a higher price for Eli Lilly's earnings, possibly due to expectations of future growth, a sentiment that is supported by the company's notable revenue growth of 29.76% over the last twelve months.

One of the InvestingPro Tips highlights that Eli Lilly has raised its dividend for 9 consecutive years, demonstrating a commitment to returning value to shareholders. Moreover, the company has maintained dividend payments for 54 consecutive years, which could be particularly appealing for income-focused investors.

For those interested in deeper analysis and additional insights, there are 20 more InvestingPro Tips available, which can be explored further with a subscription. Users can take advantage of an exclusive offer using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

Eli Lilly's continued investment in innovative treatments like tirzepatide not only addresses critical health challenges but also potentially secures its position as a prominent player in the Pharmaceuticals industry. As the company awaits FDA regulatory action, the financial metrics and InvestingPro Tips provide a broader perspective on its market standing and future potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.